Recombinant growth hormone for children and adolescents with Turner syndrome
- PMID: 17253498
- DOI: 10.1002/14651858.CD003887.pub2
Recombinant growth hormone for children and adolescents with Turner syndrome
Abstract
Background: Turner syndrome (TS) affects about one in 1500 to 2500 live-born females. One of the most prevalent and salient features of the syndrome is extremely short stature. Untreated women are approximately 20 to 21 cm shorter than normal women within their respective populations. Recombinant human growth hormone (hGH) has been used to increase growth and final height in girls who have Turner syndrome.
Objectives: To assess the effects of recombinant growth hormone in children and adolescents with TS.
Search strategy: MEDLINE, EMBASE, The Cochrane Library, LILACS, BIOSIS, Science Citation Index and reference lists were used to identify relevant trials.
Selection criteria: Randomised controlled trials were included if they were carried out in children with TS before achieving final height. Growth hormone had to be administered for a minimum of six months and compared with a placebo or no treatment control condition.
Data collection and analysis: Two reviewers assessed studies for inclusion criteria and for methodological quality. The primary outcomes were final height and growth. Secondary outcomes included bone age, quality of life, cognitive performance, and adverse effects.
Main results: Four RCTs that included 365 participants after one year of treatment were included. Only one trial reported final height in 61 treated women to be 148 cm and 141 cm in 43 untreated women (mean difference (MD) seven cm, 95% CI 6 to 8). Short-term growth velocity was greater in treated than untreated girls after one year (two trials, MD three cm per year, 95% CI 2 to 4) and after two years (one trial, MD two cm per year, 95% CI 1 to 2.3). Skeletal maturity was not accelerated by treatment with recombinant growth hormone (hGH). Adverse effects were minimally reported.
Authors' conclusions: Recombinant human growth hormone (hGH) doses between 0.3 to 0.375 mg/kg/wk increase short-term growth in girls with Turner syndrome by approximately three (two) cm in the first (second) year of treatment. Treatment in one trial increased final height by approximately six cm over an untreated control group. Despite this increase, the final height of treated women was still outside the normal range. Additional trials of the effects of hGH carried out with control groups until final height is achieved would allow better informed decisions about whether the benefits of hGH treatment outweigh the requirement of treatment over several years at considerable cost.
Update of
-
Recombinant growth hormone in children and adolescents with Turner syndrome.Cochrane Database Syst Rev. 2003;(3):CD003887. doi: 10.1002/14651858.CD003887. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003887. doi: 10.1002/14651858.CD003887.pub2. PMID: 12917993 Updated. Review.
Similar articles
-
Recombinant growth hormone for idiopathic short stature in children and adolescents.Cochrane Database Syst Rev. 2007 Jul 18;(3):CD004440. doi: 10.1002/14651858.CD004440.pub2. Cochrane Database Syst Rev. 2007. PMID: 17636758 Review.
-
Growth hormone for children with chronic kidney disease.Cochrane Database Syst Rev. 2006 Jul 19;(3):CD003264. doi: 10.1002/14651858.CD003264.pub2. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2012 Feb 15;(2):CD003264. doi: 10.1002/14651858.CD003264.pub3. PMID: 16856001 Updated. Review.
-
Recombinant growth hormone for idiopathic short stature in children and adolescents.Cochrane Database Syst Rev. 2003;(4):CD004440. doi: 10.1002/14651858.CD004440. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2007 Jul 18;(3):CD004440. doi: 10.1002/14651858.CD004440.pub2. PMID: 14584015 Updated. Review.
-
Recombinant growth hormone in children and adolescents with Turner syndrome.Cochrane Database Syst Rev. 2003;(3):CD003887. doi: 10.1002/14651858.CD003887. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003887. doi: 10.1002/14651858.CD003887.pub2. PMID: 12917993 Updated. Review.
-
Growth hormone for children with chronic renal failure.Cochrane Database Syst Rev. 2001;(4):CD003264. doi: 10.1002/14651858.CD003264. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2006 Jul 19;(3):CD003264. doi: 10.1002/14651858.CD003264.pub2. PMID: 11687179 Updated. Review.
Cited by
-
Hemophilia A and factor V deficiency in a girl with Turner syndrome: a case report.J Med Case Rep. 2023 Nov 18;17(1):480. doi: 10.1186/s13256-023-04215-2. J Med Case Rep. 2023. PMID: 37978530 Free PMC article.
-
Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet® IOS and Answer Program.J Clin Endocrinol Metab. 2023 Sep 18;108(10):2653-2665. doi: 10.1210/clinem/dgad159. J Clin Endocrinol Metab. 2023. PMID: 36947589 Free PMC article.
-
Growth in girls with Turner syndrome.Front Endocrinol (Lausanne). 2023 Jan 12;13:1068128. doi: 10.3389/fendo.2022.1068128. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36714599 Free PMC article. Review.
-
Safety and Effectiveness of Recombinant Human Growth Hormone in Children with Turner Syndrome: Data from the PATRO Children Study.Horm Res Paediatr. 2021;94(3-4):133-143. doi: 10.1159/000515875. Epub 2021 Jul 7. Horm Res Paediatr. 2021. PMID: 34350858 Free PMC article. Clinical Trial.
-
Dysgerminoma with a Somatic Exon 17 KIT Mutation and SHH Pathway Activation in a Girl with Turner Syndrome.Diagnostics (Basel). 2020 Dec 10;10(12):1067. doi: 10.3390/diagnostics10121067. Diagnostics (Basel). 2020. PMID: 33321690 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical